Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,646.40
(
1.31%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
112.46
(
0.08%
)
Bitcoin
75,812.14
(
0.05%
)
News Focus
News Focus
Post# of 257470
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122909
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 242790

Thursday, 08/25/2022 12:11:45 PM

Thursday, August 25, 2022 12:11:45 PM

Post# of 257470
PFE—Phase-3 data_for adult RSV vaccine look_good_enough_for_approval:

https://www.businesswire.com/news/home/20220825005052/en/

A separate phase-3 trial in pregnant mothers (to protect newborns) is expected to read out in 2023.

Note: PFE’s RSVpreF is an RSV vaccine—not an RSV treatment like ENTA’s EDP-938 and EDP-323. PFE’s main competitor in RSV vaccines is GSK (#msg-169113410).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now